Copelan E, Pohlman B, Rybicki L, Kalaycio M, Sobecks R, Andresen S, Dean R, Koo A, Chan J, Sweetenham J, Bolwell B
Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.
Bone Marrow Transplant. 2009 Jan;43(2):101-5. doi: 10.1038/bmt.2008.306. Epub 2008 Sep 15.
Some reports have suggested that rituximab administration before PBSC mobilization may adversely affect PBSC yield. We conducted a prospective randomized trial of PBSC mobilization using etoposide and G-CSF with or without rituximab to determine whether its addition would adversely affect CD34+ cell yield in patients with non-Hodgkin's lymphoma. Twenty seven patients were mobilized with etoposide and G-CSF and 28 with etoposide, G-CSF and rituximab. There were no adverse consequences of rituximab on CD34+ cell yield, or hematopoietic recovery or immunoglobulin levels after transplantation.
一些报告表明，在进行外周血干细胞（PBSC）动员之前给予利妥昔单抗可能会对PBSC产量产生不利影响。我们进行了一项前瞻性随机试验，使用依托泊苷和粒细胞集落刺激因子（G-CSF）进行PBSC动员，其中一组加用利妥昔单抗，另一组不加，以确定添加利妥昔单抗是否会对非霍奇金淋巴瘤患者的CD34+细胞产量产生不利影响。27例患者使用依托泊苷和G-CSF进行动员，28例患者使用依托泊苷、G-CSF和利妥昔单抗进行动员。利妥昔单抗对移植后的CD34+细胞产量、造血恢复或免疫球蛋白水平均无不良影响。
